Maurizio Averna
机构: university of palermo-school of medicine
每年引用次数
引用次数
引用: 24,682
H-指数: 68
I10-指数 : 231
出版物: 727
A controlled trial on the hypolipidemic effect of Acipimox in type IIA and IIB hyperlipoproteinemia
M. A. Averna , A. Stanzial , F. Bonafanti , G. di Fede
Springer, Dordrecht 455 -461
1987
Formation of platelet thromboxane in a patient with type I glycogenosis
Benigno , Davì G , D'Alessandro G , La Grutta A
Recenti progressi in medicina 76 ( 12) 619
1985
[Calcitonin inhibition of insulin-stimulated gastric secretion. A possibility of selective evaluation of gastric secretory function].
Picone Ab , Brancato L , Di Gesù G , Averna M
Archivio per le scienze mediche 136 ( 4) 531
1979
Ventricular arrhythmias in hypertensive patients with mild metabolic alterations.
Busà A , Sorrentino F , Averna M , Nigro P
Minerva Cardioangiologica 51 ( 1) 63 -70
1
2003
IDENTIFICATION OF A HETEROZYGOUS COMPOUND INDIVIDUAL WITH AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA HARBOURING IN THE LDL-R GENE AND IN THE PCSK9 GENE
Maurizio Averna , Alberto Notarbartolo , Angelo Baldassare Cefalu , Rosalia Caldarella
2005
A NOVEL LOSS OF FUCTION MUTATION OF PCSK9 GENE IN CAUCASIANS WITH LOW PLASMA LDL-CHOLESTEROL
Tarugi P , Daniela Pollaccia , Maurizio Averna , Angelo Baldassare Cefalu
2007
LIPIDOMICS OF FATTY LIVER IN NAFLD AND HCV INFECTION: LIVER SPHYNGOLIPIDS AND FATTY ACIDS
Antonio Craxi , Salvatore Petta , Maurizio Averna , Minà M
2011
REDUCTION OF CHOLESTEROL WITH NUTRACEUTICAL: RESULTS OF A DOUBLE BLIND STUDY
Maurizio Averna , Carlo Maria Barbagallo , Panno D , Antonina Giammanco
2013
Associazione tra aterosclerosi carotidea, disfunzione endoteliale e steatosi epatica in una popolazione con sindrome metabolica
Ida Maria Muratori , Egle Corrado , A Terranova , S Corsale
Minerva Cardioangiologica 116 -118
2007
THERAPEUTIC LIFESTYLE CHANGES: L’ALIMENTAZIONE
M. Averna
LIPID DISORDERS 24 -27
2005
Effetti biologici del resveratrolo. Dalla sperimentazione alla supplementazione
P. Iannella , Roberto Manfredi , C. Grassi , N. Silvestris
THERAPEUTICA 1 67 -86
2007
Correlazione in 309 pazienti coronaropatici tra i livelli di HDL-colesterolo e l’estensione della coronaropatia
V. Pernice , A. Pace , M. Rizzo , A. Frasheri
Italian heart journal: official journal of the Italian Federation of Cardiology 2 134 -134
2001
Effect of the −420C/G variant of the resistin gene promoter on metabolic syndrome, obesity, myocardial infarction and kidney dysfunction
G. D. Norata , M. Ongari , K. Garlaschelli , G. Tibolla
Journal of Internal Medicine 262 ( 1) 104 -112
50
2007
[4] EZETIMIBE/SIMVASTATIN COMPARED WITH DOUBLING THE DOSE OF SIMVASTATIN IN HIGH CARDIOVASCULAR RISK PATIENTS NOT AT LDL-C TARGET WITH SIMVASTATIN ALONE: THE DIALOGUE STUDY
M. Averna , A. Zaninelli , C. Le Grazie , G.F. Gensini
Nutrition Metabolism and Cardiovascular Diseases 19
1
2009
Thromboxane B2 formation and platelet sensitivity to prostacyclin in insulin-dependent and insulin-independent diabetics.
Giovanni Davi , GB Rini , M Averna , S Novo
Thrombosis Research 26 ( 5) 359 -370
72
1982
Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society
Marina Cuchel , Eric Bruckert , Henry N Ginsberg , Frederick J Raal
European Heart Journal 35 ( 32) 2146 -2157
2014
PS166 Efficacy and Safety of Alirocumab According to Smoking Status
A.C. Sposito , F.A. Fonseca , M. Averna , L.V. Lee
Global heart 11 ( 2)
2016
590 IN VITRO FUNCTIONAL CHARACTERIZATION OF NOVEL AMINO ACID SUBSTITUTIONS IN PCSK9 FOUND IN HYPOCHOLESTEROLEMIC SUBJECTS
E Pinotti , E Di Leo , C Valenti , B Cefalù
Atherosclerosis Supplements 12 ( 1) 124 -125
2011
MS42 IMPROVED LIPID REDUCTION AND TARGET ATTAINMENT WITH EZETIMIBE/SIMVASTATIN VERSUS ROSUVASTATIN IN HIGH-RISK PATIENTS FAILING PRIOR STATIN THERAPY: AGE FACTOR
L. Missault , H. Vaverkova , M. Farnier , M. Averna
Atherosclerosis Supplements 11 ( 2) 118
2010
MS329 SWITCHING FROM ANY STATIN BRAND TO EZETIMIBE/SIMVASTATIN 10/20 mg IS MORE EFFECTIVE AT LOWERING PLASMA LIPIDS VERSUS ROSUVASTATIN 10 mg
P. Brudi , M. Averna , M. Farnier , L. Missault
Atherosclerosis Supplements 11 ( 2) 175 -176
2010